Supplementary Appendix.docx

In this study we performed a meta-analysis on the currently used targeting drugs for radioiodine-refractory differentiated thyroid cancer (RR-DTC) based on an extensive literature review. This should be the largest meta-analysis of this type with most extensive and comprehensive analyses of various aspects of the therapeutic effects and adverse effects of the drugs in RR-DTC. The results demonstrate the significant therapeutic effects of these drugs and support a measured strategy to balance them against the adverse effects of the drugs. This study also identifies some new drugs that show potential superior benefits in the treatment of RR-DTC, with strong promises for future progress of the field.The results of this study are presented in the manuscript. Other results, including Detailed search strategy, Egger's test results and sensitivity analysis, are included in the supplymentary appendix.

本研究依托全面的文献综述，针对当前用于放射性碘难治性分化型甲状腺癌（radioiodine-refractory differentiated thyroid cancer, RR-DTC）的靶向药物开展了一项荟萃分析。本项研究堪称同类型研究中规模最大的荟萃分析，针对RR-DTC相关药物的治疗效果与不良反应各维度展开了最为全面且深入的分析。研究结果证实了此类药物的显著治疗效果，并支持采用审慎策略以平衡其治疗收益与不良反应之间的关系。本研究同时筛选出若干新型药物，其在RR-DTC治疗中展现出潜在的优异获益前景，有望为该领域的后续发展提供强劲支撑。本研究的核心结果已在本文手稿中进行阐述。其余结果，包括详细的检索策略、Egger检验结果以及敏感性分析内容，均收录于补充附录中。